Disease modification in psoriasis
References
Griffiths CEM, Armstrong AW, Godjonsson JE, et al. Psoriasis. Lancet 2021;397(10281):1301-15.
Davidovici BB, Satter N,Jorg PC, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130:1785-96.
Magina S, Felipe P, et al. Pathophysiology of moderate to severe plaque psoriasis: Anti IL-17 towards disease modification. Drugs Today. 2021;57(5):347-57.
Nasty A, Smith C, Spurs Pl, et al. EuroGuiDerm guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol. 2021;73(2):181-93.
Suarez Farinas M, Fuentes Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease related genes. J Invest Dermatol. 2011;131(2):391-400.
Mantos TR, O Malley JT, Lowery EL, et al. Clinically resolved psoriatic lesions contain psoriatic-specific IL-17 producing alpha beta cell clones. J Clinic Invest. 2017;127:4031-44.
Deane KD, Holers VM, Rheumatoid arthritis pathogenesis, perdiction, and prevention: An an emerging paradigm shift. Arthritis Rheumatol. 2021;73(2):181-93.
Berg DR, Colombia JF,Ungaro R, et al. The role of early biologic therapy in inflammatory bowel disease. Inf Bowel Dis. 2019;25(12):1896-905.
Hakim Ben A, Thomas E, Anna B, et al. Early intervention and disease memory in psoriasis: A literature review. J Euro Acad Dermatol Venerol. 2022;1(4):307-16.
Scherzo J U,Ogdie A, Merola J F, et al. Preventing psoriatic arthritis: Focusing on patients with psoriasis at risk of transition. Nat Rev Rheumatol. 2019;15:153-6.
Francesco B, Andera C, Stefano P, et al. Could targeted pharmacotherapies exert a ‘disease modification effect’ in patients with chronic plaque psoriasis. Int J Mol Sci. 2022;23(21):12849-64.
